With the singular exception of punctal or canalicular occlusion, when we are talking about in-office dry eye disease ...

Previously, the Company had received CRLs in November 2023 and April 2025 due to insufficient evidence in addressing the ...

The FDA has, for a third time, declined to approve reproxalap for the treatment of dry eye disease, according to a press ...

Shares of Aldeyra Therapeutics ALDX plunged 70.7% on Tuesday after the company announced receiving a Complete Response Letter (CRL) from the FDA for a third time for the new drug application (NDA) ...

In its complete response letter, the FDA said Aldeyra had failed to demonstrate reproxalap’s efficacy in adequate and ...

After delaying its review, the FDA has rejected Aldeyra Therapeutics’ experimental dry eye disease treatment for the third time. | After delaying its review, the FDA has rejected Aldeyra Therapeutics’ ...

Women over 50 face increased eye health risks post-menopause due to hormonal shifts. Conditions like dry eye, cataracts, glaucoma, and age-related macular degeneration become more prevalent.

Fluctuating vision is the most frequently cited complaint, exceeding classic discomfort symptoms, and may divert patients toward refractive explanations before DED is recognized and treated.

Used the gel for dry eyelids. Twice a day for the first few days, now once a day. Completely cleared up with a couple of ...

Aldeyra Therapeutics Inc. (NASDAQ:ALDX) said it has received a Complete Response Letter from the U.S. Food and Drug Administration rejecting its New Drug Application for reproxalap, a proposed ...

Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated diseases, today announced ...

Addison-based Premier Vision of Dallas is helping families understand childhood myopia and the importance of early ...